R87.614
Cytologic evidence of malignancy on smear of cervix
Clinical Classification Guidelines
Medical Intelligence & Overview
Cytologic evidence of malignancy on a cervical smear refers to findings from a Pap test or other cytology procedures that suggest the presence of cancerous cells on the cervix. This diagnosis indicates that abnormal cells have been detected in the cervical tissue, and further evaluation and management are essential to determine the extent of the abnormality and appropriate treatment options. Early detection of cervical malignancy through cytology can significantly improve treatment outcomes and prognosis.
Causes & Symptoms
Clinical Causes: Persistent infection with high-risk human papillomavirus (HPV) strains Chronic inflammation or irritation of the cervix Genetic predisposition or family history of cervical cancer Immunosuppression, such as from HIV/AIDS or immunosuppressive medications Lifestyle factors like smoking and long-term use of oral contraceptives Exposure to environmental carcinogens
Key Symptoms: Unusual vaginal bleeding, especially after intercourse or between periods Uncharacteristic vaginal discharge, which may be watery, bloody, or foul-smelling Pelvic pain or discomfort Pain during intercourse Pelvic or lower back pain in advanced stages
Diagnostic & Treatment
Diagnosis Path: Diagnosis begins with a cytological examination of cells collected from the cervix, usually through a Pap test. If abnormal or suspicious cells are identified, further assessments such as colposcopy, biopsy, and imaging tests may be recommended to confirm the presence of malignancy, evaluate its extent, and stage the disease.
Treatment Protocols: Management of cervical malignancy depends on the stage and severity of the disease, as well as the overall health of the patient. Common treatment options include: - Surgical procedures, such as excisional surgeries (e.g., LEEP, cone biopsy) or hysterectomy - Radiation therapy to destroy cancer cells - Chemotherapy to target malignant cells systemically - Targeted therapy or immunotherapy in specific cases A multidisciplinary team of healthcare providers will tailor the treatment to achieve the best possible outcome and address any side effects or complications.
Clinical Advice & FAQs
Billing Guidance
Is R87.614 a billable ICD-10 code?
Yes, R87.614 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report R87.614?
Clinical documentation must specify the nature of Cytologic evidence of malignancy on smear of cervix and any associated comorbidities for accurate reporting.
Cite this Clinical Reference